




Valeo Stands for Innovation, Innovation Sparks Life /
Valeo根植创新，创新激发活力

Corporate Presentation

/ 公司报告

June, 2022 / 2022年6月

(TSX: VPH)
(OTCQB: VPHIF)
(FSE: VP2)



Forward-Looking Statements: / 前瞻性陈述

This presentation, including the documents incorporated by reference herein, contains “forward-looking information” as defined under Canadian securities laws (collectively, “**forward-looking statements**”). All statements other than statements of historical fact contained in this presentation are forward-looking statements, including, without limitation, the Company’s business focus as a Canadian specialty pharmaceutical company and its focus on certain therapeutic areas, the Company’s statements regarding the Company’s business and the environment in which it operates, the forecasted asthma market size, the nature and magnitude impact of Redesca®, Enerzair® and Ateectura® sales on the Company’s future revenues, factors expected to drive the Company’s profitability and EBITDA, the Company’s anticipated positive cash flow position, information with respect to the Company’s future financial and operating performance, the Company’s future development activities and the costs and timing of those activities, the market position and market size for the Company’s products, other product-related objectives and adequacy of financial resources. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “projects” or “believes”, “pro forma” or variations (including negative and grammatical variations) of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will”, “occur” or “be achieved” and similar words or the negative thereof. Although management of the Company believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.

The forward-looking statements in this presentation are based on certain assumptions, and assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including expected revenues from certain contracts, and the ability of the Company to achieve its goals. There are no guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements, including, but not limited to, the factors discussed under the heading “Risk Factors” in the Company’s Annual Information Form available at www.sedar.com. The Company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

This presentation contains future-oriented financial information and financial outlook information (collectively, “**FOFI**”) as defined under Canadian securities laws, prepared by management of the Company about the Company’s reasonably estimated prospective results of operations, revenue, cash flows, and components thereof, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraphs. Readers are cautioned that FOFI are not guarantees of future performance, and should not be considered as such, since actual results may differ materially from those expressed in FOFI. The Company and its management believe that FOFI has been prepared on a reasonable basis, reflecting management’s best estimates and judgments. The Company disclaims any intention or obligation to update or revise any FOFI contained in this presentation, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law. Readers are cautioned that the FOFI contained in this document should not be used for purposes other than for which it is disclosed herein.

Overview / 概述

- Founded in 2003 / 创建于2003年
- Fully integrated pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada / 致力于在加拿大实现创新处方产品商业化的全面综合制药公司
- Licenses / acquires Canadian rights to innovative, clinically de-risked, commercial stage, proprietary drugs / 许可/收购加拿大的创新、临床去风险、商业阶段的专利药物的权利
- Recurrent product revenue growth / 经常性产品收入增长
- Strong Commercial Pipeline with \geq \$150M peak sales potential / 强大的商业渠道，峰值销售潜力 \geq \$1.5亿
- 100+ employees / 100多名员工
- TSX listed (March 2022) / 多交所上市（2022年3月）



Capital Structure / 资本结构

SHARES/TRADING / 股票/交易	
Share Price (as at June 7, 2022) / 股价（截止2022年6月7日）	\$0.50
52 Week High / 52周高点	\$1.12
52 Week Low / 52周低点	\$0.45
Average Daily Volume / 平均日成交量	~50K / 约5万
CAPITALIZATION / 资本化	
	MILLIONS / 百万
Shares Outstanding / 发行在外股票	81.6
Options/RSUs (avg. price, \$0.88) / 期权/限制性股票(均价\$0.88)	6.5
Warrants (avg. strike price \$1.02) / 认股权证（平均行权价\$1.02）	27.1
Convertible debentures (\$25.7M) / 可转换债券（\$2570万）	23.6
Fully-Diluted Shares Outstanding / 完全摊薄后发行在外股票	138.8
Market Capitalization (as at June 7, 2022) / 市值（截止2022年6月7日）	~\$40M / 约\$4000万

Management & Insiders
aligned with shareholders. /
管理层和内部人士与股东利益一
致

62% ownership / 持股比例62%
(52% fully diluted) / （完全摊薄
后52%）

TSX: VPH

TSX: VPH.WT

TSX: VPH.WT.A

TSX: VPH.DB



2 Business Units / 两个业务部门

Respiratory / 呼吸疾病产品



Respiratory: / 呼吸疾病产品

**ENERZAIR®
ATECTURA®**

Specialty Products / 特别产品



**Spec.
Products: / 特
别产品:**

**REDESCA®
M-ESLON®**



**Neurology: /
神经疾病产品:**

ONSTRYV®



**Oncology:
/ 肿瘤产品:**

**YONDELIS
®**

Growing Portfolio of Commercial Products / 商业产品不断增加



RESPIRATORY / 呼吸疾病产品		Launched / 启动	Est. Peak Sales / 预估销售额峰值
ENERZAIR®	Asthma / 哮喘	2021	\$90-115M / \$9000万-1.15亿
ATECTURA®	Asthma / 哮喘	2021	\$30-40M / \$3000-4000万



SPECIALTY PRODUCTS / 特别产品			
REDESCA®	Blood Thinner / 血液稀释剂	2021	\$30-35M / \$3000万-\$3500万
M-ESLON®	Pain (Tablet) / 镇痛 (片剂)	2016	\$10-15M / \$1000万-\$1500万
AMETOP™	Topical Analgesic / 局部镇痛	2020	\$1-2M / \$100万-\$200万
HESPERCO®	Immune system / 免疫系统	2020	\$1-2M / \$100万-\$200万



NEUROLOGY / 神经疾病产品			
ONSTRYV®	Parkinson's Disease / 帕金森氏病	2019	\$2-4M / \$200万-\$400万




ONCOLOGY			
YONDELIS®	Soft-Tissue Sarcoma / 软组织毒瘤	2020	\$1-2M / \$100万-\$200万

Total Estimated Peak Sales from existing portfolio of commercial products : \$165M - \$215M / 现有商业产品组合的峰值销售总额预计为: \$1.65亿- \$2.15亿

Building Canadian Pharmaceutical Growth / 推动加拿大制药业的增长


Valeo's rapidly growing revenue stream – Commercialized Product Portfolio / Valeo快速增长的收入来源 - 商业化的产品组合



*** Accounting for the current product portfolio only / *仅对当前的产品组合进行核算**

Fully Integrated Capabilities / 全面整合的能力


Valeo has all the required capabilities and the full infrastructure to register and properly manage internally its growing product portfolio through all stages of commercialization / Valeo拥有所有必要的能力和完整的基础设施，可以注册和内部适当管理其不断增长的产品组合通过商业化的各个阶段。



Makes Valeo the partner of choice for anyone looking to partner their products in Canada / 使 Valeo成为在加拿大寻求产品合作的人的首选合作伙伴



Respiratory Business Unit / 呼吸疾病产品业务部门



Innovative Asthma Therapies / 创新的哮喘治疗方法



First-In-Class / 首创



Total addressable Enerzair Market / Enerzair可满足的市场总量

350,000
PATIENTS / 35万
患者



\$90M - \$115M /
\$9000万 - \$1.15亿
150,000 patients /
15万患者
42.8%

Best-In-Class / 同类最优



Total addressable Atecura Market / Atecura可满足的市场总量


615,000
PATIENTS / 61.5万
患者



\$30M-40 M / \$3000万-
\$4000万
88,000
14.3%

What is Asthma / 什么是哮喘？

Asthma is a chronic inflammatory disease of the airways that causes symptoms like shortness of breath, chest tightness, coughing and wheezing. Asthma causes inflammation and narrowing of the bronchial tubes, which leads to **limited airflow and difficulty breathing** / 哮喘是一种慢性气道炎症性疾病，引起气短、胸闷、咳嗽和气喘等症状。哮喘导致支气管发炎和变窄，从而导致气流受限和呼吸困难。



Unmet medical needs and Care Gaps in Asthma / 未满足的喘病医疗需求和护理缺口

3.8 Million Canadians suffer from Asthma / **380万加拿大人**患有哮喘¹

317 Canadians are diagnosed with Asthma every day / 每天有**317名加拿大人**被诊断出患有哮喘³

1.4 Millions Canadians under a chronic treatment / **140万加拿大人**正在接受慢性治疗²

250,000 Canadians⁴ impacted by Severe Asthma / **25万加拿大人**⁴受到严重哮喘的影响

over 70,000 ER visits⁶ In 2015, from Asthma attacks / 在2015年，**超过7万次的急诊室就诊**⁶由哮喘发作引起

Source: (1) Public Health Agency Canada ; (2) Canadian Institute of Health Information; (3) IQVIA ; (3) The Ontario Asthma Surveillance Information System ; (4) Statistics Canada ; (5) Cost Risk Analysis for Chronic Lung Disease in Canada ; (6) CIHI ; (7) 2019 Annual Asthma Survey Report, Asthma Canada / 来源：（1）加拿大公共卫生署；（2）加拿大卫生信息研究所；（3）IQVIA；（3）安大略省哮喘监测信息系统；（4）加拿大统计局；（5）加拿大慢性肺病成本风险分析；（6）CIHI；（7）2019年度哮喘调查报告，加拿大哮喘协会





While 47% believed their asthma is controlled, 60% reported trouble sleeping due to asthma symptoms and 65% reported avoiding exercise or physical activities because of asthma symptoms⁷. / 虽然47%的人认为他们的哮喘得到了控制，但60%的人报告称因哮喘症状难以入睡，65%的人报告称因哮喘症状而避免运动或体育活动⁷。

Inhaled Treatment Options / 吸入治疗方案

SEVERITY / 严重程度	AGENT(S) / 制剂	# DRUGS / # 药物	EFFECTS / 疗效	DRUG TYPE / 药物类型
MILD / 轻度	SINGLE AGENT / 单一制剂	1	Reduces inflammation / 减少炎症 Or / 或 Reduces narrowing of airways / 减少气道狭窄	Corticosteroid / 皮质类固醇 LAMA / LAMA（长效抗胆碱能药物） LABA / LABA（沙美特罗）
MODERATE / SEVERE / 中度/重度	DUAL AGENT / 二联制剂	2	Combination drug that reduces inflammation while relaxing airways / 在放松气道的同时减轻炎症的复合药物	Corticosteroid / LABA / 皮质类固醇/ LABA（沙美特罗）
	TRIPLE AGENT / 三联制剂	3	Three drugs combination reducing inflammation while relaxing airways / 三种药物组合，减少炎症的同时放松气管	Corticosteroid / LABA / LAMA / 皮质类固醇 / LABA（沙美特罗） / LAMA（长效抗胆碱能药物）



Strong growth of triple agents expected / 预计三联制剂强劲增长



*\$630M in 2020, growing 2% every year (projected \$695M in 2025) / *2020年为\$6.3亿，每年增长2%（预计2025年为\$6.95亿）

**Maintenance = Chronic treatment of asthma / **维持治疗 = 哮喘的慢性治疗

***IQVIA data, projection of the asthma market / ***IQVIA数据，对哮喘市场的预测



Triple Therapy Asthma Product / 三联 制剂哮喘产品

Launch:	/ 推出:	Q4-2021 / 2021年第四季度
Status:	/ 状态:	Approved by Health Canada in June 2020 / 于2020年6月获得加拿大卫生部批准
Indication:	/ 适应症:	Asthma / 哮喘
Value:	/ 价值:	First triple agent (LABA/LAMA/ICS) approved for asthma treatment / 第一个被批准用于治疗哮喘的三联制剂 (LABA (沙美特罗) /LAMA (长效抗胆碱能药物) /ICS(吸入性糖皮质激素))
Partner:	/ 合作伙伴:	Novartis Pharma Canada / 诺华制药加拿大公司



Double Agent Asthma Product: 双联制剂哮喘产品:

Launch:	Q4-2021
推出:	2021年第四季度
Status:	Approved by Health Canada in April 2020
状态:	2020年4月获得加拿大卫生部批准
Indication:	Asthma
适应症:	哮喘
Value:	Next generation dual agent therapy LABA/ICS
价值:	下一代双联制剂治疗LABA（沙美特罗）/ICS(吸入性糖皮质激素)
Partner:	Novartis Pharma Canada
合作伙伴:	诺华制药加拿大分公司

Source : IQVIA -IMS / 来源 : IQVIA -IMS


ENERZAIR[®] / ATECTURA[®] Clinical Results

ENERZAIR[®] / ATECTURA[®] 临床结果



First in class triple combination ICS/LABA/LAMA /
同类最优三联用药: ICS(吸入性糖皮质激素)/LABA
(沙美特罗) /LAMA (长效抗胆碱能药物)

ENERZAIR
vs
ADVAIR



-42%


Reduction of
exacerbation / 减少
恶化¹

ENERZAIR
Vs
LOOSE TRIPLE

+96ml



Improvement of
lung function /
肺部功能改善²



-43%


Reduction of
moderate exacerbation /
减少中度恶化²

1) Iridium trial 2) Argon trial / 1) 铱试验 2) 氩试验



Best in class dual combination LABA/ICS /
同类最优的LABA (沙美特罗) /ICS(吸入性糖皮
质激素)双联合用药

ATECTURA
vs
ADVAIR



1) Palladium trial / 钯试验

KOL endorsement/ Patient Experience / 关键意见领袖认可/患者体验

ONTARIO / 安大略省

I have been so pleased with the results of switching my patients to Atecura or Enerzair. My patients say they just feel so much better. One patient asked me why I didn't put him on Enerzair earlier. / 我对患者改用Atecura或Enerzair后的效果非常满意。我的患者说他们感觉好多了。一位患者问我为什么不早点让他使用Enerzair。

Simple - My triple therapy of choice is Enerzair. It works so well. / 很简单--我选择的三联疗法是Enerzair。它的效果非常好。

Atecura made a huge difference to my patient's life. I started him on Atecura, and after one month, his FEV1 improved to 70% and this patient said he never felt so good, and was now walking to work and doing things he never did. / Atecura给我的患者的生活带来了巨大变化。我让他开始使用Atecura，一个月后，他的FEV1提高到70%，这位患者说他从来没有感觉这么好过，现在可以走路去上班并做他从未做过的事情。

With recent ODB listings for Enerzair and Atecura, these are some great new options to consider for patients on ODB. / 随着最近Enerzair和Atecura上市用于治疗脑器质性疾病（ODB），它们都是让ODB患者考虑的很好的新选择。

WESTERN CANADA / 加拿大西部

My experience to date with Atecura has been very positive. The first time I tried a patient on Atecura, she noticed immediate relief. This patient was experiencing ongoing symptoms with her current therapy. Now, she is well control and symptom free. After seeing the positive results with Atecura, I have switched several of my patients to Atecura and I am seeing similar results. / 到目前为止，我对Atecura的体验非常积极。我第一次让患者服用Atecura时，她的病情立即得到缓解。这个患者在目前的治疗中出现了持续的症状。现在，她得到了很好的控制并且没有任何症状。看到Atecura的积极效果后，我把我的几个患者的疗法换成了Atecura，我看到了类似的疗效。

The Breezhaler device is simple to use and very discrete compared to some other Asthma inhalers. It also provides confirmation each and every time they use their asthma inhaler. / 与其他一些哮喘吸入器相比，Breezhaler设备使用简单并且非常独立。还能在患者每次使用哮喘吸入器时进行确认。

QUEBEC / 魁北克省

Atecura and Enerzair in a Breezhaler are a game changer to my patients with polypharmacy. / Breezhaler中的Atecura和Enerzair多药疗法是改变我的患者的突破性疗法。



Enerzair changed the life of one of my severe asthmatic patients. She tried every inhaler in the past and since she started using Enerzair, she feels better and breaths easily. / Enerzair改变了我一个严重哮喘患者的生活。她过去尝试了所有的吸入器，自从她开始使用Enerzair后，她感觉好多了，呼吸也很轻松。

Respiratory Unit Commercial Activity / 呼吸疾病业务部门商业活动

- Head count: / 人数: 60 Person team deployed across Canada / 60人的团队部署在加拿大各地
- Target audience: 目标受众: 12,000 physicians: 2,000 specialists : 10,000 GPs / 12,000名医生: 2,000名专家 : 10,000名全科医生
- Doctor calls: / 医生问诊: 50,000 per year / 每年50,000次
- Reimbursement: / 报销: Private coverage at 90% / 私人保险覆盖为90%
Public coverage: All provinces (B.C. being finalized) / 公共保险覆盖率: 所有省份 (卑诗省正在敲定)

Growing « total prescription » trends / 增长的“总处方”趋势


PAGE 20



Weekly trend on Respiratory / 呼吸疾病药物的每周趋势


McKesson tracking – Enerzair + Ateectura (May 22)

/ McKesson追踪 - Enerzair + Ateectura (5月22日)





Specialty Products Business Unit / 特别产品业务部门



Specialty Products Business Unit

特别产品业务部门



SPECIALTY PRODUCTS / 特别产品				
REDESCA®	Blood Thinner / 血液稀释剂	Transformative / 变革性	2021	\$30-35M / \$3000-\$3500万
M-ESLON®	Pain (Tablet) / 疼痛 (片剂)	Base / 基础	2016	\$10-15/ \$1000-\$1500万
AMETOP™	Topical Analgesic / 局部镇痛剂	Base / 基础	2020	\$1-2M / \$100-\$200万
HESPERCO®	Immune system / 免疫系统	Base / 基础	2020	\$1-2M / \$100-\$200万

NEUROLOGY / 神经疾病

ONSTRYV®	Parkinson's Disease / 帕金森病	Base / 基础	2019	\$2-4M / \$200-\$400万
----------	----------------------------	-----------	------	-----------------------

ONCOLOGY / 肿瘤

YONDELIS®	Soft-Tissue Sarcoma / 软组织肉瘤	Base / 基础	2020	\$1-2M / \$100-\$200万
-----------	-----------------------------	-----------	------	-----------------------






Specialty Product: Redesca® (Biosimilar) / 特别产品: Redesca® (生物仿制药)

Launch:	Q2-2021
推出:	2021第二季度
Status:	Approved by Health Canada in December 2020
状态:	2020年12月获加拿大卫生部批准
Indication:	Prevents deep vein thrombosis and pulmonary embolism
适应症:	预防深静脉血栓和肺栓塞的发生
Team:	Valeo's dedicated team of 12 HC
团队:	Valeo的由12个HC组成的专门团队
Partner:	Shenzhen Techdow Pharmaceuticals, (World largest Heparin manufacturer)
合作伙伴:	深圳天道医药 (世界上最大的肝素制造商)


LMWH Biosimilar Market insight / LMWH生物仿制药市场分析

Enoxaparin MS / 依诺肝素市场份额



	May-21	Jun-21	Jul-21	Aug-21	Sept-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22
NOROMBY	0%	0%	0%	0%	0%	0%	0%	0%	3%	2%	2%	5%
INCLUNOX	0%	1%	1%	1%	2%	4%	7%	6%	8%	8%	9%	11%
REDESCA	16%	2%	10%	11%	13%	11%	10%	10%	15%	20%	23%	19%
LOVENOX	84%	97%	89%	88%	85%	85%	83%	83%	74%	71%	66%	65%

Biosimilar MS / 生物仿制药市场份额




	May-21	Jun-21	Jul-21	Aug-21	Sept-21	Oct-21	Nov-21	Dec-21	Jan-22	Feb-22	Mar-22	Apr-22
REDESCA		80%	90%	92%	85%	73%	61%	61%	58%	68%	69%	54%
INCLUNOX					14.8%	26%	39%	38%	32%	26%	25%	32%
NOROMBY							0.1%	1.9%	10.3%	5.6%	5.9%	14%

TSA Mar 2021 – Projected May 2022 / TSA 2021年3月 - 预计2022年5月



Quarterly Profitability FY-2020/22 / 财务年度的季度盈利能力 - 2020/22



- Revenue Growth from Redesca, Enerzair & Atecura to drive margin expansion and profitability expected by end of FY-22 / Redesca、Enerzair和Atecura的收入增长将推动利润率增长，预计到2022财年末将实现盈利
- Q2-22 Revenues and Margins UP 80% & 134% YoY / 2022年第二季度的收入和利润同比增长80%和134%
- Nominal incremental SG&A required to drive revenue growth post Q4-21 / 2021年第四季度后，为推动收入增长需要名义上的销售、一般和管理费用（SG&A）增长

Key success factors and Early Indicators / 关键成功因素和早期指标

Transformative Products / 变革性产品

Redesca, Enerzair & Atectura

to drive Revenue Growth with
\$30-40M / \$75-90M / \$25-35M
respective peaks of Sales / 推
动收入增长，分别达到\$3000万-
\$4000万/\$7500万-\$9000万
/\$2500万-\$3500万的销售峰值

Reimbursement / 报销

Enerzair/Atectura

- Private coverage : 90%+ / 私人
保险覆盖率: 90%以上
- Public coverage : / 公共保险覆盖
率:

- ◆ First province Nov. 21 /
第一个省份2021年11月
- ◆ All provinces by Apr. 22
到2022年4月所有省份

Redesca

- Private coverage: 90%+ / 私人保
险覆盖率: 90%以上
- Public coverage: completed /
公共保险覆盖率: 已完成

Commercial Team in Place / 商业团队已到位

70 dedicated

Sales / Medical team
in place since Q4-21 / 自
2021年第四季度以来，70名专
职销售/医疗团队已经到位

Strong target coverage / 强
大的目标覆盖率

Supportive educational
programs / 支持性的教育计划

Patient support programs /
患者支持计划

Early positive signs of product adoption / 产品

Growing brand awareness / 品
牌知名度不断提高

Excellent patient experience /
卓越的患者体验

KOL endorsement / 关键意见领
袖支持

Competitive Positioning / 有竞
争力的定位

Strong provincial support to
biosimilars / 各省对生物仿制药的
有力支持

Strong supply chain with our
partners / 与我们的合作伙伴建立
强大的供应链

Leadership / 领导团队

MANAGEMENT / 管理层

Steve Saviuk

Founder, CEO / 创始人, 首席执行官
Founder and CEO Since 2003 / 2003
年起担任创始人和首席执行官

Luc Mainville

SVP & CFO / 高级副总裁和首席财务官
Cardiome, Acerus, LAB Research,
Enobia, KPMG

Helen Saviuk

VP Operations / 运营副总裁
CPA,
Former Valeo CFO / 注册会计师,
前Valeo首席财务官

Nathalie Therrien

VP QA / Regulatory / 质量保
证/法规副总裁
25+ years QA and Regulatory
Affairs including Head of
QC at Sanofi Aventis / 25年
以上质量控制和法规事务经验,
包括在Sanofi Aventis担任质量
控制主管

Guy-Paul Allard

VP Legal / 法律副总裁
20+ years experience in
corporate and securities law /
20多年的公司法和证券法经验

Frederic Fasano

President and COO / 总裁兼首席运营官
Former Servier Canada President / 前
Servier Canada总裁
25+ years international pharma
executive experience / 25年以上的国际
制药业管理经验

Nelly Komari

SVP, Scientific & Medical Affairs / 科
学与医学事务高级副总裁
20+ years industry experience.
Previously senior executive for Akcea
Therapeutics and Sanofi / 20年以上的
行业经验。曾任Akcea Therapeutics和赛
诺菲的高管

Michelle Brien

VP HR & Talent Management / 人力资
源和人才管理副总裁
20+ years experience, Charles River,
CDPQ, Hewitt, Novartis / 20年以上经验,
曾就职于Charles River、CDPQ、Hewitt
、诺华

Jeff Skinner

VP Business Development / 业务发
展副总裁
20 years of experience in
specialty pharma and biotech BD
/ 在专业制药和生物技术业务开发领域
有20年的经验

BOARD / 董事会

Richard J. MacKay

Chairman / 董事会主席
Former Vice-Chairman of
Stiefel Laboratories / 前
Stiefel Laboratories董事会副
主席

Steve Saviuk

Founder, CEO / 创始人, 首席执行
官

Frederic Fasano

President, COO / 总裁, 首席运营
官

Vincent P. Hogue

Board Member / 董事会成员
SVP Retail, Laurentian Bank
Securities, 25 yrs capital markets
experience / 加拿大劳伦特银行证
卷公司零售部高级副总裁, 25年资本
市场经验

Maureen C. Brennan

Board Member / 董事会成员
40+ years in private and public health sector
/ 在私营和公共卫生部门工作40年以上
Former Director General Shriners Hospital /
前Shriners Hospital总院长

Michel Trudeau


Board Member / 董事会成员
Former CEO of Laurentian Bank
Securities / 前加拿大劳伦特银行证
卷公司首席执行官

Marc Léger

Board Member / 董事会成员
Former Chief Commercial Officer
of Valeo / Valeo前首席商务官

Investment Highlights / 投资亮点

- Significant growth ahead forecasted (100% YOY IN 2022) / 预计将有大幅增长（2022年同比增长100%）
- Pure commercial play (No R&D or clinical risks) / 纯商业运作（无研发或临床风险）
- Partnered with global leaders (Novartis, Zambon, Techdow...) / 与全球领先企业合作（诺华、Zambon、深圳天道.....）
- 3 Pivotal Launches completed in 2021: / 2021年完成了3个关键性举措：
 - Redesca[®], (\$30M - \$35M Peak Sales) / Redesca[®], （\$3000万-\$3500万的销售额峰值）
 - Enerzair[®], (\$90M - \$115M Peak Sales) / Enerzair[®], （\$9000万-\$1.15亿的销售额峰值）
 - Aectura[®], (\$30M - \$40M Peak Sales) / Aectura[®], (\$3000万-\$4000万的销售额峰值）
- Growing product portfolio & pipeline / 不断增长的产品组合和管线
- New structure fully operational since Q4-21 / 自2021年第四季度以来，新的结构全面运作
- Ongoing business development efforts to leverage corporate infrastructure with new rapidly accretive products / 正在进行业务开发工作，以利用公司的基础设施和新的快速增值产品
- TSX first trading day, March 29, 2022 / 多伦多证券交易所的第一个交易日：2022年3月29日
- Lower tier valuation & multiples compared to industry peers / 与业内同行相比，估值和倍数较低





Contact Us / 联系我们

PHONE / 电话

514-694-0150

EMAIL / 电邮

ir@valeopharma.com

WEB / 官网

www.valeopharma.com

